News8Plus-Realtime Updates On Breaking News & Headlines

Realtime Updates On Breaking News & Headlines

Now it’s the turn of children’s corona vaccine.

New Delhi: Approval for the use of Covaxin, the indigenous vaccine of Corona for children, may be received by September. According to the report of English news website India Today, AIIMS director Randeep Guleria has expressed hope. Guleria has said that the data for the Phase-2 and Phase-3 trials of Covaxin on children will come by September and during that time the approval of the vaccine for children can also be obtained.

Guleria says that if Pfizer and BioNTech’s vaccine is approved in India, it could be another option for children. While talking about the third wave of Corona, Guleria does not agree that children will be affected more in the third wave. He says that there is no reason to believe in this theory.

Guleria has also said that now schools should be considered for opening but it has to be kept in mind that educational institutions do not become super spreaders. For this, Guleria has advised that schools in the Containment Zone can be opened on one day except one day. Along with this, it will also have to be kept in mind that children follow the Corona protocol.

Trial on children going on in Delhi, Patna AIIMS
Many experts had said that children are likely to be the most affected in the third wave in India. In such a situation, preparations for the vaccine for children have intensified. Bharat Biotech’s Covaxin trials are being conducted on children aged 2 to 17 years at AIIMS Delhi and Patna. The Drugs Controller General of India (DGCI) had approved the second and third phase trials on children on May 12.

Cadila’s Jaykov-D is also undergoing trial on children
Cadila may apply to DGCI for emergency approval of Jaykov-D this week. The data analysis of Phase 3 of the vaccine trial is almost ready. The company has informed the government about this. Apart from adults, this vaccine is also being tested on children aged 12 to 18 years. It is being said that the company may soon trial the vaccine on children aged 5 to 12 years. If the results of the trial are encouraging, then the scope of vaccination can be expanded further.


If you have any concerns or complaints regarding this article, please let us know and the article will be removed soon. 

Raise A Concern